Chief Executive Officer & Founder
George Uy founded TRIGR in April 2018 with over 35 years of pharmaceutical and biotech leadership experience. For over 20 years, George was principally responsible for leading strategic marketing and commercial initiatives across Roche (Manila, Basel and Nutley) including establishing Roche Shanghai Commercial and launching Xeloda® in oncology in the USA . Subsequent to his tenure at Roche, George joined Abraxis Biosciences (formerly Nasdaq: ABRX now CELGENE) where he helped built out the oncology commercial organization and was responsible for all aspect of the launch from pre-marketing to commercialization of Abraxane®. George then served as Senior Vice President of Commercial Operations at Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPM) and most recently, as Chief Commercial Officer Sorrento Therapeutics (Nasdaq: SRNE), where he was instrumental in transitioning the Company from the OTC market to Nasdaq. George holds a Bachelor of Science in Medical Technology from the Cebu Institute of Medicine, Philippines.
Chief Operating Officer & Chief Financial Officer
Ms. Toledano joined TRIGR in 2018 with over 20 years of biotech related Wall Street principal investment, capital market and advisory experience. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) as EVP Corporate Development where she helped drive the Company’s hematology/oncology (IO mAbs, ADC), cellular therapy (CD-38 CAR-T, oncolytic virus) and pain franchises. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she was completed biotech equity financings (IPO, follow-on) totaling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served as a VP in the investment group of Royalty Pharma, where she focused on oncology/hematology and auto-immune monoclonal antibody investments. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
Dr. Nadeem Mirza, MD, MPH
Chief Medical Advisor
Dr. Mirza joins TRIGR with 27 years of clinical experience in oncology, hematology and bone marrow transplantation, including 12 years of clinical research at the MD Anderson Cancer Center and 15 years of clinical development and medical affairs in the biopharmaceutical industry. Dr Mirza launched several oncology therapies including Campath®, Abraxane®, Nexavar®, Clolar®, Zaltrap®, Venclexta®, and Copiktra®. Prior to joining TRIGR, Dr Mirza served as SVP, Corporate Medical Affairs at Verastem Oncology where he oversaw the Copiktra launch. Prior to Verastem, Dr Mirza served as Global Head, Hematology and Solid Tumors at Abbvie Oncology where he oversaw the Venclexta global launch. Before Abbvie, Dr Mirza was VP, Head of Oncology, North America Medical Affairs at Sanofi Oncology. Dr Mirza also held leadership roles in medical affairs and clinical development at Genzyme/Sanofi, Onyx Pharmaceuticals, Abraxis Oncology, and Berlex Oncology. Dr. Mirza earned his medical degree from the University of Punjab (Pakistan) and a MPH from the University of Texas.